1. Guidance for industry extended release oral dosage forms: development, evaluation, and application of in vitro/in vivo correlations. FDA CDER September 1997a. Available at:
https://www.fda.gov/downloads/drugs/guidances/ucm070239.pdf
2. Guideline on the pharmacokinetic and clinical evaluation of modified release dosage forms (EMA/CPMP/EWP/280/96 Corr1). CHMP November 2014a (replacing Guideline on Modified Release Oral and Transdermal Dosage Forms Section II (Pharmacokinetic and Clinical Evaluation (EMA/CPMP/EWP/280/96 Corr1)). Available at:
http://www.ema.europa.eu
/docs/en_GB/document_library/Scientific_guideline/2014/11/WC500177884.pdf.
3. Guidance for Industry SUPAC-MR: modified release solid oral dosage forms. FDA CDER September 1997b. Available at:
https://www.fda.gov
/downloads/Drugs/Guidances/ucm070640.pdf.
4. Guideline on quality of oral modified release products. CHMP March 2014b. Available at:
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/07/WC500170465.pdf
5. Roudier B, Davit B, Schütz H, Cardot JM. Impact of data base structure in a successful in vitro-in vivo correlation for pharmaceutical products. AAPS J. 2015;17(1):24–34.
https://doi.org/10.1208/s12248-014-9680-x
.